IS7843A - Morfólín afleiður til notkunar sem dópamín gerandefni í meðferð á m.a. kynferðisvanvirkni - Google Patents

Morfólín afleiður til notkunar sem dópamín gerandefni í meðferð á m.a. kynferðisvanvirkni

Info

Publication number
IS7843A
IS7843A IS7843A IS7843A IS7843A IS 7843 A IS7843 A IS 7843A IS 7843 A IS7843 A IS 7843A IS 7843 A IS7843 A IS 7843A IS 7843 A IS7843 A IS 7843A
Authority
IS
Iceland
Prior art keywords
treatment
sexual dysfunction
dopamine agonists
morpholine derivatives
morpholine
Prior art date
Application number
IS7843A
Other languages
English (en)
Inventor
Moira Norfor Allerton Charlotte
Douglas Baxter Andrew
Simon Cook Andrew
Hepworth David
Kwok-Fung Wong Stephen
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0228787A external-priority patent/GB0228787D0/en
Priority claimed from GB0308460A external-priority patent/GB0308460D0/en
Priority claimed from GB0313606A external-priority patent/GB0313606D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of IS7843A publication Critical patent/IS7843A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS7843A 2002-12-10 2005-05-12 Morfólín afleiður til notkunar sem dópamín gerandefni í meðferð á m.a. kynferðisvanvirkni IS7843A (is)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0228787A GB0228787D0 (en) 2002-12-10 2002-12-10 Morpholine dopamine agonists
GB0308460A GB0308460D0 (en) 2003-04-11 2003-04-11 Morpholine dopamine agonists
GB0313606A GB0313606D0 (en) 2003-06-12 2003-06-12 Morpholine dopamine agonists
PCT/IB2003/005683 WO2004052372A1 (en) 2002-12-10 2003-12-02 Morpholine derivatives for use as dopamine agonists in the treatment of i.a. sexual dysfunction

Publications (1)

Publication Number Publication Date
IS7843A true IS7843A (is) 2005-05-12

Family

ID=32512061

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7843A IS7843A (is) 2002-12-10 2005-05-12 Morfólín afleiður til notkunar sem dópamín gerandefni í meðferð á m.a. kynferðisvanvirkni

Country Status (37)

Country Link
EP (1) EP1572214B1 (is)
JP (3) JP3889775B2 (is)
KR (1) KR100796102B1 (is)
AP (1) AP2005003325A0 (is)
AR (1) AR042339A1 (is)
AT (1) ATE460938T1 (is)
AU (1) AU2003302878B2 (is)
CA (1) CA2508262C (is)
CO (1) CO5700781A2 (is)
CR (1) CR7869A (is)
CY (1) CY1110130T1 (is)
DE (1) DE60331769D1 (is)
DK (1) DK1572214T3 (is)
EA (1) EA009589B1 (is)
EC (1) ECSP055850A (is)
ES (1) ES2339767T3 (is)
GE (1) GEP20074272B (is)
HK (1) HK1081850A1 (is)
HN (1) HN2003000401A (is)
HR (1) HRP20050523A2 (is)
IS (1) IS7843A (is)
MA (1) MA27605A1 (is)
MX (1) MXPA05006151A (is)
MY (1) MY144338A (is)
NL (1) NL1024983C2 (is)
NO (1) NO330143B1 (is)
NZ (1) NZ540505A (is)
OA (1) OA13014A (is)
PA (1) PA8591601A1 (is)
PE (1) PE20040906A1 (is)
PL (1) PL377480A1 (is)
PT (1) PT1572214E (is)
RS (1) RS51442B (is)
SI (1) SI1572214T1 (is)
TW (1) TW200423944A (is)
UY (1) UY28117A1 (is)
WO (1) WO2004052372A1 (is)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200601985A1 (ru) * 2004-05-26 2007-04-27 Пфайзер Лимитед Новые производные индазола и индолона и их применение в качестве фармацевтических средств
MXPA06013786A (es) * 2004-05-27 2007-01-25 Pfizer Nuevos derivados de aminopiridina y su uso como farmacos.
GB0502509D0 (en) 2005-02-07 2005-03-16 Pfizer Ltd Novel salt form of a dopamine agonist
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
GB0700786D0 (en) * 2007-01-15 2007-02-21 Pfizer Ltd Morpholine dopamine agonists for the treatment of pain
CA2800219C (en) 2010-05-21 2019-03-12 Research Triangle Institute 1 - phenylmorpholine derivatives as hydroxybupropion analogues for treating drug dependence
EP2571858B1 (en) 2010-05-21 2018-06-20 Research Triangle Institute Phenylmorpholines and analogues thereof
WO2015086495A1 (en) 2013-12-11 2015-06-18 F. Hoffmann-La Roche Ag Process for the preparation of chiral 2-aryl morpholines
GB2543296A (en) * 2015-10-13 2017-04-19 Indivior Uk Ltd Dopamine D3 receptor antagonists having a morpholine moiety
EP3725768A1 (en) * 2019-04-17 2020-10-21 Newron Pharmaceuticals S.p.A. Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB851311A (en) * 1958-04-02 1960-10-12 Geigy Ag J R Morpholine compounds and their production
GB9108629D0 (en) * 1991-04-23 1991-06-12 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction

Also Published As

Publication number Publication date
EA009589B1 (ru) 2008-02-28
RS51442B (en) 2011-04-30
AR042339A1 (es) 2005-06-15
OA13014A (en) 2006-11-10
NZ540505A (en) 2007-02-23
EA200500801A1 (ru) 2005-12-29
NO330143B1 (no) 2011-02-21
RS20050445A (en) 2007-04-10
NO20052557L (no) 2005-09-06
HK1081850A1 (en) 2006-05-26
EP1572214A1 (en) 2005-09-14
NL1024983C2 (nl) 2005-02-01
JP3889775B2 (ja) 2007-03-07
NL1024983A1 (nl) 2004-06-11
MXPA05006151A (es) 2005-08-26
PL377480A1 (pl) 2006-02-06
EP1572214B1 (en) 2010-03-17
GEP20074272B (en) 2007-12-25
JP4624341B2 (ja) 2011-02-02
CY1110130T1 (el) 2015-01-14
CR7869A (es) 2005-07-08
DE60331769D1 (de) 2010-04-29
HN2003000401A (es) 2004-11-23
NO20052557D0 (no) 2005-05-26
KR20050094813A (ko) 2005-09-28
MA27605A1 (fr) 2005-11-01
SI1572214T1 (sl) 2010-07-30
JP2006511599A (ja) 2006-04-06
CO5700781A2 (es) 2006-11-30
PE20040906A1 (es) 2005-01-24
AP2005003325A0 (en) 2005-06-30
JP2006232857A (ja) 2006-09-07
AU2003302878B2 (en) 2009-04-23
DK1572214T3 (da) 2010-06-07
HRP20050523A2 (en) 2005-08-31
CA2508262C (en) 2009-12-01
ECSP055850A (es) 2005-09-20
UY28117A1 (es) 2004-07-30
TW200423944A (en) 2004-11-16
ATE460938T1 (de) 2010-04-15
WO2004052372A1 (en) 2004-06-24
JP2007084575A (ja) 2007-04-05
MY144338A (en) 2011-08-29
KR100796102B1 (ko) 2008-01-21
ES2339767T3 (es) 2010-05-25
CA2508262A1 (en) 2004-06-24
JP3920908B2 (ja) 2007-05-30
AU2003302878A1 (en) 2004-06-30
PA8591601A1 (es) 2004-12-16
PT1572214E (pt) 2010-05-06

Similar Documents

Publication Publication Date Title
IS7843A (is) Morfólín afleiður til notkunar sem dópamín gerandefni í meðferð á m.a. kynferðisvanvirkni
IS7738A (is) Þíasól efnasambönd til notkunar í meðferð á taugahrörnunar truflunum.
IS6388A (is) EP4 viðtaka valvís gerandefni í meðhöndluninni á beingisnun
IS7840A (is) 3-(3,5-díoxó-4,5-díhýdró-3H-(1,2,4)tríasín-2-ýl)-bensamíð afleiður sem P2X7-hindrar til notkunar í meðferð á bólguvaldandi sjúkdómum
IS7814A (is) Fenetanólamín afleiða í meðhöndlun á öndunarfærasjúkdómum.
HK1093503A1 (en) Pyrido 2, 1-a-isoquinoline derivatives as ddp-IV inhibitors
IS8105A (is) Lyfjablanda sem felur í sér ónæmisbæli til að nota í meðhöndlun á húðsjúkdómum
EP1773846A4 (en) INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO)
NO20035033D0 (no) Hydraulisk aktivert svivel for kjöring av ekspanderbare komponenter med produksjonsrörforlengelse
IL182212A0 (en) Indazolone derivatives as 11b-hsd1 inhibitors
PL378556A1 (pl) Nienukleozydowe inhibitory odwrotnej transkryptazy
ZA200604791B (en) Hydronopol derivatives as agonists on human ORL1 receptors
HK1080849A1 (en) Non-nucleoside reverse transcriptase inhibitors
GB0426313D0 (en) Therapeutic agents
IS8588A (is) Aðferð til að framleiða fljótleysanleg skammtaform sem fela í sér að minnsta kosti eitt fiskigelatín sem er valið á grundvelli sameindarþyngdar
PL377864A1 (pl) Pochodne 1-N-(fenylo)-2-N-(fenylo)pirazolidyno-1,2-dikarboksyamidowe jako inhibitory czynnika koagulacyjnego Xa do leczenia zakrzepic
AU2003250475A8 (en) 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors
IS7868A (is) Notkun á kortkólíberín-úrókortín kerfi í meðferð á bólguvaldandi sjúkdómum.
NO20032304D0 (no) Anvendelse av selektive dopamin D4-reseptoragonister for behandling av seksuell dysfunksjon
NO20054034D0 (no) Fremgangsmate for behandling av hypotyroidisme.
PL1663997T3 (pl) 1H-azolilo-metylo-amidy, sposoby ich wytwarzania i ich zastosowanie jako inhibitorów nitryfikacji
CL2004001507A1 (es) Compuestos derivados de espirobenzobenzazepinas sustituidos, inhibidores de receptores de vasopresina; composicion farmaceutica; utiles en el tratamiento de hipertension, disfuncion cardiaca, insuficiencia renal, entre otras.
DK1450782T3 (da) Anvendelse af et kombinationspræparat, der omfatter propionyl-L-carnitin og yderligere lægemidler, til behandling af erektil dysfunktion
WO2004058353A3 (en) Therapeutic use of selective noradrenaline reuptake inhibitors
DK1408038T3 (da) Imidazolderivater samt deres anvendelse som perifert selektive inhibitorer dopamin-beta-hydroxylase